IQ-3 is a specific inhibitor of the c-JNK family and is more selective for JNK3. IQ-3 for JNK1, JNK2, and JNK3 Kd The values are 0.24 μM, 0.29 μM, and 0.066 μM, respectively.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO ≥ 5 mg/mL|
 G David Batty, et al. Eur J Cardiovasc Prev Rehabil. Does IQ predict cardiovascular disease mortality as strongly as established risk factors? Comparison of effect estimates using the West of Scotland Twenty-07 cohort study
|Related JNK Products|
CC-90001 is a JNK (c-Jun N-terminal kinase) inhibitor that can be used as a Phase II clinical candidate to study idiopathic pulmonary fibrosis.
SU3327 is a potent, selective and substrate-competitive JNK inhibitor with an IC50 of 0.7 μM.
L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK.
Juglanin, a natural occurring flavonoid, is a JNK acticator, with inflammation and anti-tumor activities. Juglanin can induce apoptosis and autophagy on human breast cancer cells.
JNK-IN-7 is a potent JNK inhibitor with IC50 of 1.5, 2 and 0.7 nM for JNK1, JNK2 and JNK3, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.